Atika Capital Management’s Krystal Biotech KRYS Stock Holding History

Atika Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.23M	Sell	6,000 -4,625	-44%	-$1.38M	0.15%	73
2026 Q1	$2.74M	Buy	+10,625	New	+$2.83M	0.34%	57
2022 Q3	–	Sell	-30,000	Closed	-$1.97M	–	104
2022 Q2	$1.97M	Buy	+30,000	New	+$1.87M	0.22%	68
2020 Q1	–	Sell	-58,319	Closed	-$3.23M	–	95
2019 Q4	$3.23M	Hold	58,319	–	–	0.62%	58
2019 Q3	$2.03M	Buy	+58,319	New	+$2.61M	0.43%	59

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Atika Capital Management's KRYS Position: Q2 2026 in Review

Atika Capital Management reduced its Krystal Biotech (KRYS) stake by 44% in Q2 2026, selling an estimated $1.38M and leaving 6,000 shares worth $2.23M. The position accounts for 0.15% of the portfolio, ranked #73.

Atika Capital Management first reported a position in KRYS in Q3 2019 and has held it in 5 quarters since. The position peaked at $3.23M in Q4 2019. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Atika Capital Management held 6,000 shares of Krystal Biotech worth $2.23M as of Q2 2026.
Atika Capital Management sold 4,625 Krystal Biotech shares in Q2 2026, an estimated $1.38M.
Krystal Biotech made up 0.15% of Atika Capital Management's portfolio in Q2 2026, its #73 holding.
Atika Capital Management first reported a position in Krystal Biotech in Q3 2019 and has held it in 5 quarters since.
Atika Capital Management's Krystal Biotech position peaked at $3.23M in Q4 2019.
424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Atika Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.